KYMERA THERAPEUTICS, INC. Earnings Per Share (Basic)
KYMERA THERAPEUTICS, INC. (KYMR) reported Earnings Per Share (Basic) of -$0.62 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.62.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.71.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.97.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.94.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$3.69.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$2.98.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$2.52.
- KYMERA THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$2.87.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.62 10-Q · filed 2026-08-05 | -$1.33 10-Q · filed 2026-08-05 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.71 10-Q · filed 2026-04-30 | -$1.67 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.60 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.55 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.91 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.86 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.69 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.94 10-Q · filed 2025-11-04 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.71 10-Q · filed 2025-11-04 | -$3.60 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.95 10-Q · filed 2026-08-05 | -$1.77 10-Q · filed 2026-08-05 | -$2.65 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.48 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.82 10-Q · filed 2026-04-30 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.52 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.11 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-12-31 | -$0.88 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.29 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.98 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.82 10-Q · filed 2025-11-04 | -$1.40 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$2.09 10-Q · filed 2025-11-04 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | -$0.58 10-Q · filed 2025-08-11 | -$1.26 10-Q · filed 2025-08-11 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.42 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$0.69 10-Q · filed 2025-05-09 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.85 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.52 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.90 10-Q · filed 2024-10-31 | -$1.57 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$2.27 10-Q · filed 2024-10-31 | -$2.88 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.67 10-Q · filed 2024-08-07 | -$1.37 10-Q · filed 2024-08-07 | -$1.97 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.75 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.70 10-Q · filed 2024-05-02 | -$1.31 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.09 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.86 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.38 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.16 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.87 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.79 10-Q · filed 2023-11-02 | -$1.57 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$2.28 10-Q · filed 2023-11-02 | -$2.94 derived: net income ÷ weighted average shares · filed 2024-02-22 |
| 2022-06-30 | -$0.78 10-Q · filed 2023-08-03 | -$1.49 10-Q · filed 2023-08-03 | -$2.15 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$2.71 derived: net income ÷ weighted average shares · filed 2024-02-22 |
| 2022-03-31 | -$0.71 10-Q · filed 2023-05-04 | -$1.37 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.93 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$2.49 derived: net income ÷ weighted average shares · filed 2024-02-22 |
| 2021-12-31 | -$0.66 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.22 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$1.78 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$2.09 10-K · filed 2024-02-22 |
| 2021-09-30 | -$0.56 10-Q · filed 2022-11-03 | -$1.11 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.42 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$0.55 10-Q · filed 2022-08-09 | -$0.84 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | -$3.15 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |